Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: A pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and SOLO 2)

Atopic dermatitis (AD) is a chronic, predominantly type 2 inflammatory skin disease that affects up to 10% of adults and 20% of children [1 –5]. Moderate-to-severe AD is characterized by extensive eczematous lesions, pronounced persistent, severe itch [6–8], substantial pain and discomfort [9–12], and is frequently associated with other type 2 (atopic/allergic) comorbidities, e.g. asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis, and food allergies [8,13–15], and a significant disease burden, e.g.

Source: Journal of Dermatological Science - March 11, 2019 Category: Dermatology Authors: Diamant Tha çi, Eric Simpson, Mette Deleuran, Yoko Kataoka, Zhen Chen, Abhijit Gadkari, Laurent Eckert, Bolanle Akinlade, Neil M.H. Graham, Gianluca Pirozzi, Marius Ardeleanu Source Type: research